What is wrong with THLook no further than the addresses of the current board members. Not one board member from outside Quebec, let alone Canada. TH has literally looked no further than 30 miles outside its office doors to find the expertise and talent to lead this company forward on a global stage. (with the exception of 2 board members who now reside 80 miles away near Mont Tremblant Resort) Do the most qualified people for TH's board really reside in a 30 mile radius from head office? There is nowhere else in the entire world you could find someone that might bring more to the table? Does this look like a company with big goals and plans to become a global player, or does it look more like a company trying really hard to impress their friends in the Montreal business community?
Joe Arena - same old same old. Small step up in that he does not reside 30 mins from head office. It looks like he has some technical knowledge in regulatory matters that might help but you hire people for that.
No offense to anyone here, I think having small stakeholders represented on any board is a good thing but we have to set our sights higher. You can tell a lot about someone (or a company in this case) by who they surround themselves with. Who has TH chosen to surround themselves with. Barely qualified local business people. Do you think these board members have the global experience and expertise needed to move this company forward? Do you think they would exert any leadership over the company or are they a rubber stamp?
Where are the additions that can truely make a difference? If they want an ex-pfizer oncology person why not get someone that can bring a lot more to the table like this lady? Instead we get Mr Arena.
Jan. 23, 2019-- Sage Therapeutics (NASDAQ: SAGE),today announced the addition of Elizabeth (Liz) Barrett to the company’s board of directors.
Liz Barrett is the president and chief executive officer of UroGen. She previously served as chief executive officer of Novartis Oncology. In that role, she oversaw more than 10,000 associates in 85 countries and was a member of the Novartis executive committee. Prior to Novartis, she was global president, oncology at Pfizer Inc., where she held a series of leadership positions, including president, Europe, global innovative pharma, president, North America, and president, U.S. oncology business unit. Prior to Pfizer, Ms. Barrett was vice president and general manager of the oncology business unit at Cephalon Inc., where she launched the company into oncology. She has also held senior roles at Johnson & Johnson, working across their oncology, diagnostics, consumer products, and hospital and orthopedic markets sectors.